190 related articles for article (PubMed ID: 21536438)
1. Discovery of a nortropanol derivative as a potent and orally active GPR119 agonist for type 2 diabetes.
Xia Y; Chackalamannil S; Greenlee WJ; Jayne C; Neustadt B; Stamford A; Vaccaro H; Xu XL; Baker H; O'Neill K; Woods M; Hawes B; Kowalski T
Bioorg Med Chem Lett; 2011 Jun; 21(11):3290-6. PubMed ID: 21536438
[TBL] [Abstract][Full Text] [Related]
2. Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119.
Semple G; Fioravanti B; Pereira G; Calderon I; Uy J; Choi K; Xiong Y; Ren A; Morgan M; Dave V; Thomsen W; Unett DJ; Xing C; Bossie S; Carroll C; Chu ZL; Grottick AJ; Hauser EK; Leonard J; Jones RM
J Med Chem; 2008 Sep; 51(17):5172-5. PubMed ID: 18698756
[TBL] [Abstract][Full Text] [Related]
3. Discovery and biological evaluation of novel 4-amino-2-phenylpyrimidine derivatives as potent and orally active GPR119 agonists.
Negoro K; Yonetoku Y; Misawa-Mukai H; Hamaguchi W; Maruyama T; Yoshida S; Takeuchi M; Ohta M
Bioorg Med Chem; 2012 Sep; 20(17):5235-46. PubMed ID: 22836190
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profile.
Semple G; Lehmann J; Wong A; Ren A; Bruce M; Shin YJ; Sage CR; Morgan M; Chen WC; Sebring K; Chu ZL; Leonard JN; Al-Shamma H; Grottick AJ; Du F; Liang Y; Demarest K; Jones RM
Bioorg Med Chem Lett; 2012 Feb; 22(4):1750-5. PubMed ID: 22264481
[TBL] [Abstract][Full Text] [Related]
5. Design of potent and selective GPR119 agonists for type II diabetes.
Szewczyk JW; Acton J; Adams AD; Chicchi G; Freeman S; Howard AD; Huang Y; Li C; Meinke PT; Mosely R; Murphy E; Samuel R; Santini C; Yang M; Zhang Y; Zhao K; Wood HB
Bioorg Med Chem Lett; 2011 May; 21(9):2665-9. PubMed ID: 21273063
[TBL] [Abstract][Full Text] [Related]
6. Discovery and optimization of arylsulfonyl 3-(pyridin-2-yloxy)anilines as novel GPR119 agonists.
Zhang JK; Li AR; Yu M; Wang Y; Zhu J; Kayser F; Medina JC; Siegler K; Conn M; Shan B; Grillo MP; Eksterowicz J; Coward P; Liu JJ
Bioorg Med Chem Lett; 2013 Jun; 23(12):3609-13. PubMed ID: 23648181
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel orally bioavailable GPR40 agonists.
Lu H; Fei H; Yang F; Zheng S; Hu Q; Zhang L; Yuan J; Feng J; Sun P; Dong Q
Bioorg Med Chem Lett; 2013 May; 23(10):2920-4. PubMed ID: 23582779
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and structure-activity relationship of fused-pyrimidine derivatives as a series of novel GPR119 agonists.
Negoro K; Yonetoku Y; Moritomo A; Hayakawa M; Iikubo K; Yoshida S; Takeuchi M; Ohta M
Bioorg Med Chem; 2012 Nov; 20(21):6442-51. PubMed ID: 23010456
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 6,7-dihydro-5H-pyrrolo[2,3-a]pyrimidines as orally available G protein-coupled receptor 119 agonists.
Katamreddy SR; Carpenter AJ; Ammala CE; Boros EE; Brashear RL; Briscoe CP; Bullard SR; Caldwell RD; Conlee CR; Croom DK; Hart SM; Heyer DO; Johnson PR; Kashatus JA; Minick DJ; Peckham GE; Ross SA; Roller SG; Samano VA; Sauls HR; Tadepalli SM; Thompson JB; Xu Y; Way JM
J Med Chem; 2012 Dec; 55(24):10972-94. PubMed ID: 23214471
[TBL] [Abstract][Full Text] [Related]
10. GPR119 agonists for the potential treatment of type 2 diabetes and related metabolic disorders.
Shah U; Kowalski TJ
Vitam Horm; 2010; 84():415-48. PubMed ID: 21094910
[TBL] [Abstract][Full Text] [Related]
11. Discovery of structurally novel, potent and orally efficacious GPR119 agonists.
Alper P; Azimioara M; Cow C; Mutnick D; Nikulin V; Michellys PY; Wang Z; Reding E; Paliotti M; Li J; Bao D; Zoll J; Kim Y; Zimmerman M; Groessel T; Tuntland T; Joseph SB; McNamara P; Seidel HM; Epple R
Bioorg Med Chem Lett; 2014 May; 24(10):2383-7. PubMed ID: 24751443
[TBL] [Abstract][Full Text] [Related]
12. Discovery of phenylpropanoic acid derivatives containing polar functionalities as potent and orally bioavailable G protein-coupled receptor 40 agonists for the treatment of type 2 diabetes.
Mikami S; Kitamura S; Negoro N; Sasaki S; Suzuki M; Tsujihata Y; Miyazaki T; Ito R; Suzuki N; Miyazaki J; Santou T; Kanzaki N; Funami M; Tanaka T; Yasuma T; Momose Y
J Med Chem; 2012 Apr; 55(8):3756-76. PubMed ID: 22428944
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists.
Sasaki S; Kitamura S; Negoro N; Suzuki M; Tsujihata Y; Suzuki N; Santou T; Kanzaki N; Harada M; Tanaka Y; Kobayashi M; Tada N; Funami M; Tanaka T; Yamamoto Y; Fukatsu K; Yasuma T; Momose Y
J Med Chem; 2011 Mar; 54(5):1365-78. PubMed ID: 21319751
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a novel trans-1,4-dioxycyclohexane GPR119 agonist series.
Han S; Narayanan S; Kim SH; Calderon I; Zhu X; Kawasaki A; Yue D; Lehmann J; Wong A; Buzard DJ; Semple G; Carroll C; Chu ZL; Al-Sharmma H; Shu HH; Tung SF; Unett DJ; Behan DP; Yoon WH; Morgan M; Usmani KA; Chen C; Sadeque A; Leonard JN; Jones RM
Bioorg Med Chem Lett; 2015 Aug; 25(15):3034-8. PubMed ID: 26048791
[TBL] [Abstract][Full Text] [Related]
15. Discovery of pyrazolo[3,4-d]pyrimidine derivatives as GPR119 agonists.
Gillespie P; Goodnow RA; Saha G; Bose G; Moulik K; Zwingelstein C; Myers M; Conde-Knape K; Pietranico-Cole S; So SS
Bioorg Med Chem Lett; 2014 Feb; 24(3):949-53. PubMed ID: 24412066
[TBL] [Abstract][Full Text] [Related]
16. GPR119 agonists for the treatment of type 2 diabetes.
Jones RM; Leonard JN; Buzard DJ; Lehmann J
Expert Opin Ther Pat; 2009 Oct; 19(10):1339-59. PubMed ID: 19780700
[TBL] [Abstract][Full Text] [Related]
17. GPR119 agonists: a promising new approach for the treatment of type 2 diabetes and related metabolic disorders.
Shah U
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):519-32. PubMed ID: 19562648
[TBL] [Abstract][Full Text] [Related]
18. Discovery of cyclic guanidines as potent, orally active, human glucagon receptor antagonists.
Sinz C; Chang J; Lins AR; Brady E; Candelore M; Dallas-Yang Q; Ding V; Jiang G; Lin Z; Mock S; Qureshi S; Salituro G; Saperstein R; Shang J; Szalkowski D; Tota L; Vincent S; Wright M; Xu S; Yang X; Zhang B; Tata J; Kim R; Parmee E
Bioorg Med Chem Lett; 2011 Dec; 21(23):7131-6. PubMed ID: 22001094
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a potent and selective free fatty acid receptor 1 agonist with low lipophilicity and high oral bioavailability.
Christiansen E; Due-Hansen ME; Urban C; Grundmann M; Schmidt J; Hansen SV; Hudson BD; Zaibi M; Markussen SB; Hagesaether E; Milligan G; Cawthorne MA; Kostenis E; Kassack MU; Ulven T
J Med Chem; 2013 Feb; 56(3):982-92. PubMed ID: 23294321
[TBL] [Abstract][Full Text] [Related]
20. Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR40 agonists.
Takano R; Yoshida M; Inoue M; Honda T; Nakashima R; Matsumoto K; Yano T; Ogata T; Watanabe N; Toda N
Bioorg Med Chem Lett; 2014 Jul; 24(13):2949-53. PubMed ID: 24835985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
